Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome

Siddharth Kesarwani; Srikant Kumar Sahu; Soumyava Basu

doi:10.1016/j.jaapos.2011.12.153

Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome

J AAPOS. 2012 Jun;16(3):309-11. doi: 10.1016/j.jaapos.2011.12.153. Epub 2012 Mar 28.

Authors

Siddharth Kesarwani¹, Srikant Kumar Sahu, Soumyava Basu

Affiliation

¹ Miriam Hyman Children's Eye Care Centre, L V Prasad Eye Institute, Bhubaneswar, Orissa, India.

PMID: 22459106
DOI: 10.1016/j.jaapos.2011.12.153

Abstract

Bevacizumab is widely used for several ocular conditions, including age-related macular degeneration, diabetic retinopathy, corneal neovascularization, neovascular glaucoma, and retinopathy of prematurity. We describe a 14-year-old patient with Stevens-Johnson syndrome in whom subconjunctival injection of bevacizumab in one eye caused bilateral regression of corneal neovascularization.

Publication types

Case Reports

MeSH terms

Adolescent
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Bevacizumab
Conjunctiva / drug effects*
Corneal Neovascularization / drug therapy*
Corneal Neovascularization / etiology
Humans
Injections, Intraocular
Male
Stevens-Johnson Syndrome / complications*
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab